| Literature DB >> 25170382 |
Amos Haki Nsheha1, Dorothy Elizabeth Dow2, Gabriel Erick Kapanda3, Bernardus Carolus Hamel4, Levina January Msuya1.
Abstract
INTRODUCTION: Paediatric adherence to Highly Active Antiretroviral Therapy (HAART) is a dynamic process involving many factors. Adherence for the majority on therapy matters to prevent failure of 1(st) and 2(st) line therapy. The purpose of this study was to determine the rate of adherence to antiretroviral therapy in HIV infected children.Entities:
Keywords: Adherence; HAART; HIV; Tanzania; children
Mesh:
Substances:
Year: 2014 PMID: 25170382 PMCID: PMC4145266 DOI: 10.11604/pamj.2014.17.238.2280
Source DB: PubMed Journal: Pan Afr Med J
Child/caregiver's socio- demographic characteristics (n= 183)
| Variable | N (%) | |
|---|---|---|
| Children | ||
|
| ||
| Male | 92 (50.3) | |
| Female | 91 (49.7) | |
|
| ||
| Pre-adolescent (2-9 years) | 66 (36.1) | |
| Adolescent ( 10-17 years) | 117 (63.9) | |
|
| ||
| Attending school | 160 (87.4) | |
| Not attending school | 23 (12.6) | |
|
| 33 (18.0) | |
| Male | 33(18.0) | |
| Female | 150 (82.0) | |
|
| ||
| 20 – 29 | 17 (9.3) | |
| 30 – 39 | 69 (37.7) | |
| 40 or older | 97 (53.0) | |
|
| ||
| None | 5 (2.8) | |
| Primary | 113 (61.7) | |
| Post-primary | 65 (35.5) | |
|
| ||
| Single | 17 (9.3) | |
| Married | 115 (62.8) | |
| Divorced/separated | 15 (8.2) | |
| Widowed | 36 (19.7) | |
|
| ||
| Biological parent | 113 (61.7) | |
| Non biological | 70 (38.3) | |
|
| ||
| Unemployed | 29 (15.8) | |
| Employed | 154 (84.2) | |
|
| ||
| Up to 100,000 | 91 (49.7) | |
| Above 100,000 | 92 (50.3) | |
|
| ||
| Purchase | 149 (81.4) | |
| Own source | 30 (16.4) | |
| Support from relatives/friends | 4 (2.2) | |
|
| ||
| Positive | 97 (53.0) | |
| Negative | 86 (47.0) |
Medication and socio-economic factors that influence adherence to ART
| Variable | Total | Adherence status | OR (95% CI) | p-value | |
|---|---|---|---|---|---|
| Good adherence | Poor adherence | ||||
| No. (%) | No. (%) | ||||
|
| |||||
| Male | 92 | 80 (87.0) | 12 (13.0) | ||
| Female | 91 | 68 (74.7) | 23 (25.3) | 2.26 (1.05-4.87) | 0.04 |
|
| |||||
| Pre- adolescents | 66 | 50 (75.8) | 16 (24.2) | ||
| Adolescent | 117 | 98 (83.8) | 19 (16.2) | 0.61 (0.29-1.28) | 0.19 |
|
| |||||
| Fixed dose combination | 135 | 111 (82.2) | 24 (17.8) | ||
| Unfixed combination | 48 | 37 (77.1) | 11(22.9) | 1.34(0.62-3.08) | 0.438 |
|
| |||||
| Yes | 16 | 8 (50.0) | 8 (50.0) | 0.19 (0.07-0.56) | 0.001 |
| No | 167 | 140 (83.8) | 27 (16.2) | ||
|
| |||||
| Yes | 61 | 43 (70.5) | 18(29.5) | 0.40 (0.18-0.82) | 0.012 |
| No | 122 | 105(86.1) | 17 (13.9) | ||
|
| |||||
| Up to 100,000 | 91 | 68 (74.7) | 23 (25.3) | ||
| Above 100,000 | 92 | 80 (87.0) | 12 (13.0) | 0.44 (0.21-0.96) | 0.035 |
|
| |||||
| Yes | 112 | 99(84.4) | 13 (11.6) | 3.4 (1.60-7.36) | 0.001 |
| No | 71 | 49 (69.0) | 22 (31.0) | ||
|
| |||||
| Yes | 152 | 128(84.2) | 24 (15.8) | 2.93 (1.23-6.90) | 0.011 |
| No | 31 | 20 (64.5) | 11 (35.5) | ||